Dear All:As discussed in prior newsletters, BARDA is constantly working to ensure it has adequate medical countermeasures (MCMs) for a variety of possible threats. The titles of these newsletters give a quick review of their recent work -- note in particular the Fireside Chat and the newsletter discussing the ongoing BAA (Broad Agency Announcement) for antibacterial and antifungal MCMs:22 July 2025: "BARDA RFP: Antibiotic for HABP/VABP or Bloodstream Infection"5 Nov 2024: "BARDA seeks deep insight on antibacterials near/beyond end-of-Phase 2"26 Sep 2023: "BARDA Medical Countermeasures BAA: Substantial updates"12 Nov 2023: "Fireside Chat with BARDA’s Branch Chief for Antimicrobials"Continuing with their theme of seeking to understand what's available (and possibly procure products for a government stockpile), we have today the announcement by BARDA of this RFI (Request For Information):Title: "Medical Countermeasures for the Treatment of Drug-Resistant Fungal Infections"Notice ID (link to webpage and detailed RFI document): RFI-MCM-TDRFI-BARDA-2026Concept: "... gain information regarding first-in-class antifungals in development for the treatment of drug-resistant Candida species, including Candida auris, and/or drug-resistant Aspergillus species."Scope: "First-in-class small molecule or peptide-based antifungals that are currently in Phase 2 clinical trials or beyond (e.g., including FDA- or EMA-approved)."Due date: 21 June 2026While this is not a funding round (see...